Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Actinium Pharmaceuticals, Inc. on June 25, 2014. The filing reports the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 1,670,000 shares of common stock (Firm Shares) at $7.50 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 250,000 additional shares.
- Expected Net Proceeds: Approximately $11.4 million (without over-allotment) or $13.2 million (with full over-allotment exercise), after deducting underwriting discounts and offering expenses.
- Underwriter: Canaccord Genuity Inc. as representative.
- Closing Date: Expected on June 30, 2014, subject to customary conditions.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations, as this report focuses solely on the capital raising transaction.
Material Changes
The primary material change is the execution of the Underwriting Agreement to raise capital. This represents a significant increase in the company's equity capital base upon closing.
Outlook, Risks, and Contingencies
The offering is contingent upon the satisfaction of customary closing conditions. The Underwriting Agreement includes standard representations, warranties, indemnification obligations, and termination provisions. The filing references a press release issued on the same date regarding the pricing of the offering.
Key Facts for Investor Verification
- Verify the actual closing of the offering on or around June 30, 2014.
- Confirm whether the underwriters exercised the 30-day over-allotment option for the additional 250,000 shares.
- Review the final net proceeds received by the company after all expenses.
- Examine the full Underwriting Agreement (Exhibit 1.1) for specific indemnification and termination clauses.